Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)
| Status: | Completed |
|---|---|
| Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 10/1/2017 |
| Start Date: | August 2007 |
| End Date: | July 2012 |
Effect of Macrolide Treatment on a Novel Pathway of Neutrophilic Inflammation in COPD
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease. Azithromycin, an
antibiotic, may be beneficial at reducing the symptoms and severity of the disease. This
study will analyze previously collected study data to evaluate the anti-inflammatory
properties of azithromycin and determine how azithromycin affects the frequency and severity
of COPD exacerbations.
antibiotic, may be beneficial at reducing the symptoms and severity of the disease. This
study will analyze previously collected study data to evaluate the anti-inflammatory
properties of azithromycin and determine how azithromycin affects the frequency and severity
of COPD exacerbations.
COPD is a disease in which the lung airways are partly damaged and obstructed, making it
difficult to breathe. The most common cause is cigarette smoking, but breathing in other
types of lung irritants, including pollution, dust, and chemicals, over a long period of time
may also contribute to COPD. It is the fourth leading cause of death in the United States.
Symptoms include coughing, excess mucus production, shortness of breath, wheezing, and chest
tightness.
Some bacterial infections may worsen COPD exacerbations. Current studies are examining if the
macrolide antibiotic azithromycin may be beneficial at reducing the frequency and/or severity
of COPD exacerbations. Azithromycin also has anti-inflammatory properties that may reduce the
severity of COPD exacerbations by inhibiting the matrix metalloprotease (MMP)-catalyzed
breakdown of collagen and the subsequent generation of proline-glycine-proline (PGP), a
substance produced in response to collagen breakdown. An increase in PGP levels may indicate
an increase in inflammation, which can worsen COPD symptoms. NHLBI's COPD Network Macrolide
study includes people with COPD who were randomly assigned to receive either azithromycin or
placebo for 1 year. For this current study, researchers will examine the Macrolide
participants' previously collected blood samples, sputum samples, and study data, including
information on COPD exacerbations and azithromycin effects. The purpose of this study is to
examine the anti-inflammatory properties of azithromycin in people with COPD.
difficult to breathe. The most common cause is cigarette smoking, but breathing in other
types of lung irritants, including pollution, dust, and chemicals, over a long period of time
may also contribute to COPD. It is the fourth leading cause of death in the United States.
Symptoms include coughing, excess mucus production, shortness of breath, wheezing, and chest
tightness.
Some bacterial infections may worsen COPD exacerbations. Current studies are examining if the
macrolide antibiotic azithromycin may be beneficial at reducing the frequency and/or severity
of COPD exacerbations. Azithromycin also has anti-inflammatory properties that may reduce the
severity of COPD exacerbations by inhibiting the matrix metalloprotease (MMP)-catalyzed
breakdown of collagen and the subsequent generation of proline-glycine-proline (PGP), a
substance produced in response to collagen breakdown. An increase in PGP levels may indicate
an increase in inflammation, which can worsen COPD symptoms. NHLBI's COPD Network Macrolide
study includes people with COPD who were randomly assigned to receive either azithromycin or
placebo for 1 year. For this current study, researchers will examine the Macrolide
participants' previously collected blood samples, sputum samples, and study data, including
information on COPD exacerbations and azithromycin effects. The purpose of this study is to
examine the anti-inflammatory properties of azithromycin in people with COPD.
Inclusion Criteria:
- Participating in the COPD Network Macrolide study
- Clinical diagnosis of at least moderate COPD
- Cigarette consumption of 10 pack years or more
Exclusion Criteria:
- Diagnosis of asthma
- Predicted life expectancy of less than 3 years
- History of hypersensitivity to macrolide antibiotics
- Long-term kidney insufficiency
- Long-term liver insufficiency
- Prolonged QT interval
- Use of medications that may prolong the QT interval
We found this trial at
1
site
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Click here to add this to my saved trials
